Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MT-302 |
Synonyms | |
Therapy Description |
MT-302 are lipid nanoparticles containing mRNA encoding a chimeric antigen receptor (CAR) targeting TROP2, which may induce tumor killing (Cancer Res 2023;83(8_Suppl):Abstract nr LB027, Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MT-302 | MT302|MT 302 | MT-302 are lipid nanoparticles containing mRNA encoding a chimeric antigen receptor (CAR) targeting TROP2, which may induce tumor killing (Cancer Res 2023;83(8_Suppl):Abstract nr LB027, Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05969041 | Phase I | MT-302 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) | Recruiting | AUS | 0 |